Trial results

A Study of CS060380 Tablets in Patients With MASH and Obesity

NCT07466017 on ClinicalTrials.gov · last registry update 2026-08-10

Closed to new participants; the 130 already enrolled are still being followed. Due to report 30 April 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Percentage change in liver fat content from baseline to Week 36 (MRI-PDFF). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Cascade Pharmaceuticals, Inc

Sponsor type

Other

Enrollment

130

Started

2026-04-02

Primary completion

2027-04-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage change in liver fat content from baseline to Week 36 (MRI-PDFF)

Conditions studied

Metabolic Dysfunction-associated Steatohepatitis (MASH) · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.